Cargando…
Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
One of the major limitations in the clinical use of existing oxazolidinone antibiotics is their characteristic adverse reactions, in particular thrombocytopenia. In anti-infective treatment, if patients are suspected of having drug-induced thrombocytopenia, the first step is to immediately discontin...
Autores principales: | Li, Bi, Liu, Ying, Luo, Jiaqi, Cai, Yun, Chen, Mengli, Wang, Tianlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165100/ https://www.ncbi.nlm.nih.gov/pubmed/37168994 http://dx.doi.org/10.3389/fphar.2023.1157437 |
Ejemplares similares
-
Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus
por: Gao, Shan., et al.
Publicado: (2023) -
A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
por: Guo, Qi, et al.
Publicado: (2021) -
Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
por: Wu, Junzhen, et al.
Publicado: (2023) -
Contezolid: First Approval
por: Hoy, Sheridan M.
Publicado: (2021) -
Easy Access to Evans’ Oxazolidinones. Stereoselective Synthesis and Antibacterial Activity of a New 2-Oxazolidinone Derivative
por: Diaz, Gaspar, et al.
Publicado: (2014)